12:00 AM
May 28, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

NovoThirteen catridecacog regulatory update

EMA's CHMP issued a positive opinion recommending approval of NovoThirteen catridecacog from Novo Nordisk to treat congenital Factor XIII deficiency, a bleeding...

Read the full 89 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >